# Medical Question & Answer

**Sample ID**: a8780a2c-9cb7-45e5-b781-8641e6ce0e55
**Dataset Index**: 3567

---

## Question

DOSIS DE FUROSEMIDA PARA PACIENTE CON INICIO DE DIALISIS PERITONEAL

---

## Answer

> Let's see… What do we have here? The user is asking about the appropriate dosing of furosemide for a patient who is starting peritoneal dialysis, including whether dose adjustment is needed, what dose to start with, how to titrate, and how to monitor and integrate with peritoneal dialysis strategy and residual kidney function considerations. Let's break this down step-by-step. First, I need to think about the pharmacology of furosemide and its relevance in dialysis. Then, I should verify regulatory guidance on dose adjustment in peritoneal dialysis. Next, I will review guideline and trial data for practical dosing ranges and titration. After that, I need to consider residual renal function and PD-specific fluid management goals. Finally, I will outline monitoring, safety, and a concrete dosing plan with contingencies for anuria and special situations.

> Let me first confirm the pharmacologic rationale and labeled indications. Furosemide is a loop diuretic indicated for edema associated with heart failure, liver cirrhosis, and kidney disease, and it is not removed by hemodialysis, which implies that dialysis does not meaningfully alter its clearance or necessitate routine dose reduction solely due to dialysis status, though clinical response will vary with residual kidney function and volume status [^116upV7c] [^11429yge].

> Wait, let me verify the regulatory stance on dose adjustment in peritoneal dialysis. Multiple FDA sources indicate that furosemide use is acceptable in PD patients with no dose adjustment required for oral, IV, or subcutaneous formulations, which supports continuing or initiating standard dosing without automatic reduction when PD begins [^116kz56K] [^1155WvU1] [^114twrwX].

> Hold on, let's not jump to conclusions; I should confirm practical dosing ranges from guidelines and clinical studies. The Renal Association guideline explicitly recommends enhancing residual diuresis with diuretics, citing frusemide 250 mg daily as an example, which aligns with the high-dose range often used in advanced CKD and dialysis populations to overcome diuretic resistance and augment natriuresis and urine volume [^114QQ2jD]. Let me also check supportive data: a randomized trial in incident CAPD patients showed that furosemide 250 mg daily increased urine volume by roughly 176 mL/day at 6 months and attenuated the decline in urine output compared with controls, without preserving GFR, which supports using high-dose furosemide to augment diuresis when clinically indicated [^1114Hrbo].

> I need to ensure I integrate PD-specific fluid management goals. PD programs often aim for adequate ultrafiltration while minimizing exposure to hypertonic glucose, and diuretics can reduce reliance on high-glucose solutions. Observational guidance suggests vigilance when daily ultrafiltration falls below about 750 mL in anuric patients, prompting reassessment of the PD prescription and consideration of modality adjustments, underscoring why augmenting residual diuresis with furosemide can be strategically useful early in PD [^112oRFxh]. Let me reconsider the role of low-sodium PD solutions and RAAS blockade. Contemporary reviews emphasize salt restriction, icodextrin use, and antihypertensives as first-line strategies, with diuretics as adjuncts to optimize volume and blood pressure control in PD [^111raXxR].

> Next, I should review how residual kidney function modifies diuretic response. Furosemide requires secretion into the tubular lumen to act, so as GFR declines, higher doses are typically needed to achieve the same natriuretic effect; this is why starting doses in advanced CKD are often 40–80 mg orally and may escalate to several hundred milligrams in resistant cases, acknowledging diminishing returns once true anuria supervenes [^1164oTPh]. But wait, what if the patient becomes anuric? In that scenario, loop diuretics lose their mechanistic target and should be tapered and discontinued while fluid management shifts toward PD ultrafiltration optimization and, if needed, icodextrin or modality re-evaluation [^112oRFxh].

> Let me think about monitoring and safety. I should confirm electrolyte surveillance, especially for hypokalemia and hyponatremia, along with renal function, volume status, and blood pressure at each PD visit, and track 24-hour urine volume and clearances at least every 4–6 months to quantify residual kidney function contribution and guide ongoing diuretic need [^116bkeY7]. I should double-check the risk of furosemide toxicity; overdosage manifests as dehydration, hypotension, and electrolyte disturbances, and supportive care is the mainstay, so vigilant lab and clinical monitoring is essential when using high-dose regimens in PD patients [^11429yge].

> I will now examine the role of mineralocorticoid antagonism as an adjunct. Spironolactone 25–50 mg daily has RCT-level evidence in PD showing reductions in left ventricular mass and improved ejection fraction over 24 months without excess hyperkalemia when combined with ACEi/ARB, so in appropriate patients with reduced residual function and LVH, it can be layered with furosemide for synergistic volume and cardiac effects, though potassium must be closely monitored [^111LiqrA].

> Let me formulate a concrete dosing plan and verify it aligns with evidence. In a patient initiating PD with residual diuresis, a reasonable starting point is oral furosemide 40–80 mg once daily, titrating by 40–80 mg increments every 3–5 days to effect, with a typical target of 160–250 mg daily in divided doses if urine output remains suboptimal and volume status or blood pressure warrants augmentation; this range is supported by guideline exemplars and trial data showing benefit at 250 mg daily, while recognizing that some patients may require higher doses if GFR is very low and others may not respond once anuria develops [^114QQ2jD] [^1114Hrbo]. Hold on, I should verify administration logistics; in cases of poor oral absorption or severe edema, IV or subcutaneous formulations can be used without dose adjustment, and fixed-ratio SC furosemide is FDA-cleared for edema in CKD, which can facilitate outpatient diuretic delivery when needed [^116kz56K] [^114twrwX].

> Hmm, wait a minute, I almost concluded that "standard eGFR-based dose adjustments apply", but that would be misleading in dialysis. I should clarify: furosemide labeling does not mandate dialysis-specific dose reductions, yet clinical response is tightly linked to residual kidney function; therefore, titration should be driven by urine output, volume status, blood pressure, and patient goals rather than a fixed dialysis-based formula, with dose escalation until diuretic resistance or anuria supervenes, at which point tapering is appropriate [^116kz56K] [^1114Hrbo] [^111raXxR].

> Next, I should review how to integrate this with PD prescription adjustments. If diuretic-optimized residual diuresis remains insufficient to meet volume goals, consider switching a long dwell to icodextrin, using low-sodium PD solutions in selected hypertensive patients, and aligning exchange frequency with peritoneal transport characteristics to enhance ultrafiltration before escalating glucose tonicity, thereby balancing fluid removal with membrane preservation and metabolic goals [^114QQ2jD] [^115CFCLx] [^111raXxR].

> Final recommendation: Start oral furosemide 40–80 mg daily at PD initiation and titrate in 40–80 mg steps to a usual target of 160–250 mg daily in divided doses if residual diuresis persists and clinical goals are unmet, continuing standard PD monitoring of volume, blood pressure, electrolytes, and residual kidney function. If urine output ceases, discontinue furosemide and pivot to PD-only volume strategies, with consideration of RAAS blockade and spironolactone in appropriate patients to support blood pressure and cardiac remodeling targets [^1114Hrbo] [^114QQ2jD] [^111LiqrA] [^112oRFxh].

---

En pacientes con inicio de diálisis peritoneal, **la furosemida no requiere ajuste de dosis** por la DP [^1155WvU1] y puede usarse para fomentar la diuresis residual y facilitar el control de volumen [^116okQZL] [^114QQ2jD]. La dosis habitual es **40–120 mg/día VO**, ajustándose según respuesta diurética y estado de volumen [^116okQZL]; en caso de resistencia, puede escalarse hasta 250 mg/día [^1114Hrbo] [^114QQ2jD]. Vigilar electrolitos y función renal, y suspender si hay anuria o reacciones adversas [^notfound].

---

## Farmacocinética de furosemida en diálisis peritoneal

La furosemida se elimina principalmente por vía renal; sin embargo, **en DP no requiere ajuste de dosis** [^116kz56K] porque el fármaco no se dializa significativamente y su eliminación no depende de la depuración peritoneal [^notfound].

---

## Indicaciones y objetivos del uso de furosemida en DP

En DP, la furosemida se usa para:

- **Fomentar la diuresis residual**: Aumenta el volumen de orina y la excreción de sodio, ayudando al control de volumen y reduciendo la necesidad de soluciones hipertonicas de glucosa [^1114Hrbo] [^116okQZL] [^114QQ2jD].
- **Control de hipertensión**: Reduce el volumen plasmático y la carga de sodio, mejorando el control de la PA [^116okQZL].
- **Prevención de complicaciones cardiovasculares**: Menor sobrecarga de volumen y mejor control de PA pueden reducir eventos cardiovasculares [^notfound].

---

## Recomendaciones de dosis según la literatura y guías clínicas

| **Fuente** | **Recomendación de dosis** | **Comentarios** |
|-|-|-|
| Guía Renal Association (2017) | 250 mg/día VO | Recomendado para mejorar la diuresis residual y reducir el uso de soluciones hipertonicas [^114QQ2jD] |
| Estudio clínico (Kidney International, 2001) | 250 mg/día VO | Aumentó significativamente el volumen de orina en pacientes en CAPD [^1114Hrbo] |
| Revisión de la literatura (Seminars in Dialysis, 2016) | 40–120 mg/día VO, ajustable según respuesta | Recomendado para optimizar el control de volumen y la diuresis residual [^116okQZL] |

---

Estas fuentes respaldan un rango de **40–120 mg/día VO**, con ajuste según respuesta y tolerancia, y hasta 250 mg/día en casos de resistencia diurética [^1114Hrbo] [^114QQ2jD].

---

## Método de administración y ajuste de dosis

- **Vía oral**: Forma preferente por comodidad y adherencia.
- **Ajuste de dosis**: Modificar según respuesta diurética, volumen de orina, estado de volumen y electrolitos.
- **Monitorización**: Control regular de potasio, sodio, creatinina y volumen de orina para ajustar la dosis y detectar efectos adversos [^notfound].

---

## Efectos secundarios y precauciones

La furosemida suele bien tolerarse en DP, pero puede causar:

- **Hipokalemia**: Requiere monitorización y corrección.
- **Hiponatremia**: Menos frecuente pero posible.
- **Deshidratación**: Ajustar dosis según estado de volumen.
- **Ototoxicidad**: Rara, más común con dosis altas IV.

En caso de anuria o reacciones adversas significativas, **suspender el fármaco** y reevaluar la estrategia de manejo de volumen.

---

## Consideraciones especiales en el inicio de diálisis peritoneal

En el inicio de DP, la furosemida **no requiere ajuste de dosis inicial** y puede continuar o iniciarse según la diuresis residual y los objetivos clínicos [^1155WvU1] [^114QQ2jD]. Su uso se ajustará según la respuesta diurética y la función renal residual, con monitorización estrecha de electrolitos y estado de volumen [^notfound].

---

## Resumen de recomendaciones

- **Dosis inicial**: 40–120 mg/día VO, ajustable según respuesta [^notfound].
- **Dosis máxima**: Hasta 250 mg/día en casos de resistencia diurética [^1114Hrbo] [^114QQ2jD].
- **Monitorización**: Control regular de electrolitos y función renal.
- **Ajuste de dosis**: Según respuesta diurética y estado de volumen.
- **Suspensión**: En caso de anuria o reacciones adversas significativas.

---

La furosemida **no requiere ajuste de dosis** en el inicio de DP y se usa para fomentar la diuresis residual y el control de volumen, con dosis típicas de 40–120 mg/día VO y hasta 250 mg/día en casos de resistencia, con monitorización estrecha de electrolitos y función renal.

---

## References

### Risperidone (Perseris) [^116GqfGb]. FDA (2025). Medium credibility.

Regarding the use of risperidone ER SC (also known as Uzedy, Perseris) in patients with peritoneal dialysis:

- Do not use.

---

### Factors related to patient selection and initiation of peritoneal dialysis [^112cFNLK]. The Journal of Vascular Access (2017). Low credibility.

The majority of dialysis patients initiate dialysis using hemodialysis, rather than peritoneal dialysis (PD), although they may be candidates for either modality. Multiple factors account for this selection, including pre-dialysis education, physician familiarity with hemodialysis versus PD, and patient-related factors. This paper will discuss the various considerations by both providers and patients in the selection of PD as a modality.

---

### Fesoterodine fumarate [^113L7Vjf]. FDA (2025). Medium credibility.

Regarding the use of fesoterodine ER PO in patients with peritoneal dialysis:

- Dose as in eGFR < 30 mL/min/1.73 m². Maximal dose of 4 mg per day.

---

### Furosemide [^116kz56K]. FDA (2025). Medium credibility.

Regarding the use of furosemide IV (also known as Lasix, Furoscix) in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.

---

### Managing hospitalized peritoneal dialysis patients: ten practical points for non-nephrologists [^115ju82q]. The American Journal of Medicine (2021). Medium credibility.

Although nephrologists are responsible for the long-term care of dialysis patients, physicians from all disciplines will potentially be involved in the management of patients with kidney failure, including patients on peritoneal dialysis, the major home-based form of kidney-replacement therapy. This review aims to fill knowledge gaps of non-experts in peritoneal dialysis and to highlight key management aspects of in-hospital care of patients on peritoneal dialysis, with a focus on acute scenarios to facilitate prompt decision-making. The clinical pearls provided should enable non-nephrologists to avoid common pitfalls in the initial assessment of peritoneal dialysis-related complications and guide their decision regarding when to refer their patients to a specialist, resulting in improved multidisciplinary patient care.

---

### Barium sulfate (vizumax HD) [^111F7y9s]. FDA (2021). Medium credibility.

PRECAUCIONES

PRECAUCIONES: General: los procedimientos que implican el uso de medios de contraste radiopacos deben llevarse a cabo bajo la dirección de personal con la capacitación requerida y con un conocimiento profundo del procedimiento particular que se realizará. Los antecedentes de asma bronquial, atopia, como lo evidencian la fiebre del heno y el eccema, o una reacción previa a un agente de contraste, merecen especial atención. Se debe tener precaución con el uso de medios radiopacos en pacientes severamente debilitados y en aquellos con hipertensión marcada o enfermedad cardiaca avanzada. No se recomienda la ingestión de bario en pacientes con antecedentes de aspiración de alimentos. Tenga cuidado si administra este producto a pacientes en quienes se desconoce la integridad del mecanismo de deglución. Si se aspira bario en la laringe, se debe interrumpir inmediatamente la administración posterior. Después de cualquier estudio con bario del tracto gastrointestinal, puede ser importante rehidratar al paciente lo más rápido posible para evitar la impactación del bario. Para evitar la impactación del bario en el colon, también puede ser necesario el uso de laxantes suaves como leche de magnesia o lactulosa después de la finalización del examen. Estos laxantes suaves se recomiendan de forma rutinaria y en pacientes con antecedentes de estreñimiento a menos que esté clínicamente contraindicado.

---

### Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study [^113qGiPH]. BMC Nephrology (2021). Medium credibility.

Case presentation

Patient n.1

A 78-year-old woman suffering from End Stage Kidney Disease showed high BP levels resistant to antihypertensive treatment. Written informed consent was obtained from the patient for publication of this case report.

She had a medical history characterized by at least 10 years of poor BP control, despite use of three anti-hypertensives (doxazosin 4 mg, amlodipine 10 mg, telmisartan 80 mg) and a diuretic (furosemide 250 mg) at the maximum tolerated dose. A low salt diet (< 100 mmol/day) had also been prescribed. Physical examination showed no lower-limb edema or any signs of volume expansion. Ultrasound disclosed that the left kidney was reduced in size, whereas the contralateral kidney showed a high intrarenal resistance index (0.82) suggestive of atherosclerotic reno-vascular disease, with unilateral renal artery stenosis, as the apparent cause of resistant hypertension. The patient refused radiological intervention, so in view of the kidney function deterioration (serum Creatinine: 5.14 mg/dL estimated GFR by CKD-EPI: 6 mL/min/1.73 m²) and poor BP control, she was put on continuous ambulatory PD (CAPD) using 3 times 2-L exchanges of 1.36% standard PD solution (Dianeal, Baxter® sodium:132 mmol/L) and an empty abdomen during the nocturnal hours.

After 3 months of CAPD, BP levels persisted elevated (mean Home BP: 152/80 mmHg,), despite euvolemia revealed by echocardiography (collapsibility of inferior vena cava). We therefore performed ABPM (SpaceLabs Healthcare®) to exclude pseudo-resistant hypertension. ABPM yelded poor control of mean 24 h-BP (152/81 mmHg), mean diurnal (151/83 mmHg) and mean nocturnal BP (153/75 mmHg), with an inversion of the circadian rhythm (systolic night/day ratio: 1.02). Considering that antihypertensive treatment was still optimal, we switched from standard PD (132 mEq/L) to a low sodium PD solution using 1.4% glucose bags with a sodium concentration of 130 mEq/L (DextroCore LS, Iperboreal Pharma, Italy). The CAPD schedule was confirmed.

---

### Furosemide injection 80 mg / 10 mL (Furoscix) [^111TRG7c]. FDA (2025). Medium credibility.

1 INDICATIONS AND USAGE

FUROSCIX is indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.

FUROSCIX is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. (1)

---

### Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome [^114gJBGu]. European Journal of Endocrinology (2023). High credibility.

Síndrome de ovario poliquístico (SOP) 2023 international evidence-based guideline — scope, methods, and key outputs are as follows: The guideline targets consistent, evidence-based care and includes 254 recomendaciones y puntos de práctica, and the earlier 2018 guideline is now used in 196 países. Development followed AGREEII and GRADE methodology with broad engagement spanning 71 países; over 12 meses the process addressed 59 preguntas clínicas priorizadas that included 52 revisiones sistemáticas y 3 narrativas. The technical evidence report comprised 6000 páginas supporting 77 recomendaciones basadas en evidencia and 54 recomendaciones de consenso, con 123 puntos de práctica. Key updates include refined individual diagnostic criteria with un algoritmo de diagnóstico simplificado and la inclusión de los niveles de la hormona anti-Mulleriana (AMH) como alternativa al ultrasonido en adultos.

---

### Furosemide (Lasix) [^1155WvU1]. FDA (2025). Medium credibility.

Regarding the use of furosemide PO (also known as Lasix, Furoscix) in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.

---

### APD prescription: achieving the adequacy goals [^117J8Kwv]. Seminars in Dialysis (2002). Low credibility.

In the last few years, automated peritoneal dialysis (APD) has undergone considerable improvements due to technological developments. The definition of a minimal dose of peritoneal dialysis (PD) has not yet been completely assessed. Appropriate use of APD requires an evaluation of dialytic efficiency in terms of dialytic indexes and their targets. Many dialytic treatment modalities have been performed in order to achieve adequacy targets. Some aspects have to be taken into consideration to reach the optimal dialytic dose: optimizing mass transfer in correlation with intraperitoneal volumes, prescribing tailored treatment modalities according to different characteristics of peritoneal membranes and individual patient needs, and performing more biocompatible treatments using different glucose profiling and alternative physiologic PD fluids. New high-flow techniques such as continuous flow PD can ensure better urea and creatinine clearances and ultrafiltration rates, leading to a higher utilization of the APD modality.

---

### Evidence on continuous flow peritoneal dialysis: a review [^116nbKZA]. Seminars in Dialysis (2022). Medium credibility.

Based on the limited available data, CFPD appears to provide improved (small solute) clearance compared with conventional PD, in particular at higher dialysate flow rates (> 100 mL/min) and in patients with high (‐average) transport status. When performed for 8 h per day, small solute clearances approach the time‐averaged clearances of intermittent HD (~11 mL/min for urea [or a weekly standard Kt/V of ~2.2], ~7 mL/min for creatinine with thrice weekly HD). Therewith, CFPD may become a more attractive alternative for HD, in particular for patients without residual diuresis. Also, improvements in ultrafiltration efficiency were reported in CFPD, therewith potentially reducing glucose‐related toxicity to the peritoneal membrane and possibly also adverse systemic metabolic effects of excessive intraperitoneal glucose absorption, although this was not explored in any study thus far. In addition, CFPD may be used in the treatment of other causes of hypervolemia as well, such as heart failure. However, there are virtually no data available on long‐term CFPD (n = 6 patients with treatment ≥ 7 months), neither with regard to outcome nor treatment tolerability. Lowering of plasma levels of (pathogenic) uremic toxins and lower daily glucose load, as well as improved volume status, may all contribute to improvements in outcome parameters. These may include "hard" parameters such as mortality and (co)morbidity, as well as patient‐related (and patient‐reported) parameters such as quality of life, necessity for diet restrictions, pill burden, and uremic symptoms. Of note, the ADEMEX trial found that a limited increase in creatinine clearance (~35%) and peritoneal Kt/V (~40%) did not result in a survival advantage. Still, the expected large improvement in clearances achieved with CFPD in combination with reduced glucose burden may result in improvements in "hard" endpoints.

---

### Nifedipine [^115S3xjH]. FDA (2024). Medium credibility.

Regarding the use of nifedipine PO and SL in patients with peritoneal dialysis:

- Reduce starting dose.
- Monitor renal function. Monitor for hypotension and peripheral edema.

---

### Barium sulfate (vizumax ENEM) [^111XXScz]. FDA (2021). Medium credibility.

PRECAUCIONES

General: los procedimientos que implican el uso de medios de contraste radiopacos deben llevarse a cabo bajo la dirección de personal con la capacitación requerida y con un conocimiento profundo del procedimiento particular que se realizará. Los antecedentes de asma bronquial, atopia, como lo evidencian la fiebre del heno y el eccema, o una reacción previa a un agente de contraste, merecen especial atención. Se debe tener precaución con el uso de medios radiopacos en pacientes severamente debilitados y en aquellos con hipertensión marcada o enfermedad cardiaca avanzada. No se recomienda la ingestión de bario en pacientes con antecedentes de aspiración de alimentos. Tenga cuidado si administra este producto a pacientes en quienes se desconoce la integridad del mecanismo de deglución. Si se aspira bario en la laringe, se debe interrumpir inmediatamente la administración posterior. Después de cualquier estudio con bario del tracto gastrointestinal, puede ser importante rehidratar al paciente lo más rápido posible para evitar la impactación del bario. Para evitar la impactación del bario en el colon, también puede ser necesario el uso de laxantes suaves como leche de magnesia o lactulosa después de la finalización del examen. Estos laxantes suaves se recomiendan de forma rutinaria y en pacientes con antecedentes de estreñimiento a menos que esté clínicamente contraindicado.

---

### Peritonitis within a patient on automated peritoneal dialysis [^111U8BVc]. BMJ Case Reports (2018). Medium credibility.

Outcome and follow-up

To date, the patient has not been readmitted due to peritonitis. The patient was controlled regularly by taking blood samples every fourth week for the next few months in the outpatient clinic.

---

### Triamterene (Dyrenium) [^111xXefC]. FDA (2024). Medium credibility.

Regarding the use of triamterene PO (also known as Dyrenium) in patients with peritoneal dialysis:

- Do not use.
- May cause acute kidney injury
Potassium-sparing diuretic: ineffective in moderate to severe renal failure.

---

### Furosemide (Lasix) [^113ADgkE]. FDA (2025). Medium credibility.

Regarding the use of furosemide PO (also known as Lasix, Furoscix) in patients with chronic liver disease, any severity:

- Use with caution.
- Monitor serum aminotransferases.
- Therapy should not be instituted until the basic condition is improved.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid = 2c9b4d8f-0770–482d-a9e6–9c616a440b1a.

---

### Utilization of PD modalities: evolution [^1178hkew]. Seminars in Dialysis (2002). Low credibility.

In the early 1960s, peritoneal dialysis (PD) was introduced as a form of long-term maintenance therapy in patients with end-stage renal disease (ESRD). We have come a long way since. Increasing understanding of peritoneal kinetic behavior, its innovative manipulation to meet patient needs, critical monitoring of clinical outcomes, and parallel development in technology have all contributed to the worldwide success of the therapy over the past four decades. In this article we review the evolution of the various PD modalities in the context of these factors.

---

### Evidence on continuous flow peritoneal dialysis: a review [^115ug2GH]. Seminars in Dialysis (2022). Medium credibility.

7 DISCUSSION

CFPD is a promising PD modality which seems to offer improved small solute clearance and improved ultrafiltration efficiency as compared to conventional PD. However, the currently available data make it difficult to draw solid conclusions, in particular with regard to long‐term effects.

The currently available data are limited by a variety of factors. First, only a small number of well‐controlled clinical trials have been performed. Many reports reviewed here are case series or conference abstracts. These report types are prone to bias (e.g. indication bias and reporting bias), hamper accurate interpretation of the results due to individualized treatments (e.g. different dialysate flow rates within/between subjects) and generally prevent careful review of the methods and results due to brief reporting (abstracts) or high variability (case series). Second, most studies only included a limited number of patients (in this review overall n = 79 for human studies) and/or performed a limited number of dialysis sessions within a limited study duration, with the majority of the studies performing only one or two CFPD session(s) per patient (overall > 281 sessions) within ≤ 3 days (range one session to ~11 months). Third, detailed study information was often lacking, for example on patient characteristics (e.g. age, weight, transport status, residual diuresis, and renal clearance), treatment methods (e.g. dialysate flow, initial fill volume, and description of the conventional treatment schedule), and outcome parameters (e.g. solute clearance, MTAC, and UF), complicating accurate interpretation and extrapolation of the study results. Finally, there is considerable heterogeneity regarding the methods employed (e.g. number, type and location of the catheter[s], rate and mode [continuous or rapid cycling] of the dialysate flow, and use of fresh or regenerated dialysate), which also makes it difficult to draw conclusions.

---

### Furosemide (Lasix) [^112N2ZDx]. FDA (2025). Medium credibility.

Regarding the use of furosemide PO (also known as Lasix, Furoscix) in patients with continuous renal replacement:

- Use acceptable.
- No dose adjustment required.

---

### Pyrimethamine (Daraprim) [^117PAtsC]. FDA (2021). Medium credibility.

Regarding the use of pyrimethamine PO (also known as Daraprim) in patients with peritoneal dialysis:

- Use with caution.

---

### Five-year time profiles of clearances of different uremic solutes in incident peritoneal dialysis patients [^112PcBFQ]. American Journal of Nephrology (2025). Medium credibility.

Statement of Ethics

This study protocol was reviewed and approved by the Ethical Committee of Zhongshan Hospital, Fudan University, approval No. B2017–108R. Written informed consent was obtained from all the patients.

---

### Clinical practice guidelines for hemodialysis adequacy, update 2006 [^116bkeY7]. American Journal of Kidney Diseases (2006). Medium credibility.

Hemodialysis residual kidney function — measurement and monitoring: To measure RKF, Kr can be calculated from a 24-hour urine collection for urea clearance, and for peritoneal dialysis (PD), 24-hour urine collections should be obtained at least every 4 months or when a decrease in RKF is suspected.

---

### Ceftazidime [^116mZajB]. FDA (2023). Medium credibility.

Regarding the use of ceftazidime IM (also known as Fortaz, Tazicef) in patients with peritoneal dialysis:

- Reduce dose.
- Start at a dose of 500 mg. Maximal dose of 1 g. Maximal frequency of q24h.

---

### Assessment and management of hypertension among patients on peritoneal dialysis [^111raXxR]. Clinical Journal of the American Society of Nephrology (2019). Medium credibility.

Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important differentiation between PD and in-center hemodialysis. However, the burden of hypertension and prognostic association of BP with mortality follow comparable patterns in both modalities. Although management of hypertension uses similar therapeutic principles, long-term preservation of residual diuresis and longevity of peritoneal membrane function require particular attention in the prescription of the appropriate dialysis regimen among those on PD. Dietary sodium restriction, appropriate use of icodextrin, and limited exposure of peritoneal membrane to bioincompatible solutions, as well as adaptation of the PD regimen to the peritoneal transport characteristics, are first-line therapeutic strategies to achieve adequate volume control with a potential long-term benefit on technique survival. Antihypertensive drug therapy is a second-line therapeutic approach, used when BP remains unresponsive to the above volume management strategies. In this article, we review the available evidence on epidemiology, diagnosis, and treatment of hypertension among patients on PD and discuss similarities and differences between PD and in-center hemodialysis. We conclude with a call for randomized trials aiming to elucidate several areas of uncertainty in management of hypertension in the PD population.

---

### Renal association clinical practice guideline on peritoneal dialysis in adults and children [^115xTpMi]. BMC Nephrology (2017). Low credibility.

Lay summary

These guidelines cover all aspects of the care of patients who are treated with peritoneal dialysis. This includes equipment and resources, preparation for peritoneal dialysis, and adequacy of dialysis (both in terms of removing waste products and fluid), preventing and treating infections. There is also a section on diagnosis and treatment of encapsulating peritoneal sclerosis, a rare but serious complication of peritoneal dialysis where fibrotic (scar) tissue forms around the intestine. The guidelines include recommendations for infants and children, for whom peritoneal dialysis is recommended over haemodialysis.

Immediately after the introduction there is a statement of all the recommendations. These recommendations are written in a language that we think should be understandable by many patients, relatives, carers and other interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or 2 depending on the strength of the recommendation by the authors, and A-D depending on the quality of the evidence that the recommendation is based on.

---

### Hyaluronic acid [^112YAmmi]. FDA (2020). Medium credibility.

Precautions and Warnings

* Si se observase derrame articular extraerlo antes de inyectar Maxiostenil.

* Es necesario seguir la técnica correcta de la inyección intraarticular en condiciones completamente asépticas.

Ver Instrucciones de uso y manipulación.

* Como en cualquier procedimiento intraarticular, es recomendable evitar la sobrecarga de la articulación

tratada, inmediatamente después de la inyección intraarticular.

* Los pacientes deben ser cuidadosamente examinados antes de la administración de Maxiostenil para

determinar posibles signos de inflamación agudos y el médico debe evaluar cuidadosamente la oportunidad del

inicio de la terapia.

* Se debe observar particular atención en pacientes con infecciones o alteraciones de la piel en zonas próximas

al punto de inyección para evitar la posibilidad de desarrollar artritis bacteriana.

* Guardar fuera del alcance de los niños.

---

### A patient on peritoneal dialysis with refractory volume overload [^115j7Ppw]. Clinical Journal of the American Society of Nephrology (2016). Low credibility.

The management of volume in patients with diabetes on peritoneal dialysis is affected by several factors, including the degree of residual renal function, peritoneal membrane small-solute transport, salt and water intake, blood sugar control, comorbidity, and nutritional status. It requires sequential evaluation of volume status and adjustment of the peritoneal dialysis prescription on the basis of assessments of membrane function and alterations in urine volume. Steps should be taken to preserve residual renal function for as long as possible. Ultimately, in patients who have become anuric and have developed ultrafiltration failure, timely transfer to hemodialysis may be necessary, requiring discussion and planning with the patient.

---

### Barium sulfate (vizumax ENEM) [^111fopuv]. FDA (2021). Medium credibility.

Los pacientes aprensivos pueden desarrollar debilidad, palidez, tinnitus, diaforesis y bradicardia después de la administración de cualquier agente de diagnóstico. Tales reacciones son generalmente de naturaleza no alérgica.

REACCIONES ADVERSAS:Las reacciones adversas que acompañan el uso de formulaciones de sulfato de bario son infrecuentes y generalmente leves, aunque se han producido reacciones graves (aproximadamente 1 en 500,000) y muertes (aproximadamente 1 en 2,000,000). Las complicaciones del procedimiento son raras, pero pueden incluir neumonitis por aspiración, impactación con sulfato de bario, formación de granuloma, intravasación, embolización y peritonitis después de perforación intestinal, episodios vasovagales y sincopales y muertes. Se ha demostrado que los cambios de EKG ocurren después o durante los enemas de suspensión de sulfato de bario. Es de la mayor importancia estar completamente preparado para tratar cualquier evento de este tipo.

---

### Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients [^1119mFMm]. BMC Nephrology (2020). Medium credibility.

13 HFrEF patients (12.1%) and 8 HFpEF patients (21.6%) were treated with erythropoiesis stimulation agents (ESA) pre-pUF. This number increased to 18.6% in HFpEF and 37.5% in HFrEF at 12 months. In patients without ESAs or being on stable dosages of ESAs, we initially detected a significant increase of haemoglobin after 3 months (HFrEF from 11.3 ± 1.74 mg/dl to 11.9 ± 1.71 mg/dl, P = 0.024 and HFpEF from 10.8 1.68 to 11.7 ± 2.12, P = 0.038). Results improved but without significance at the end of the observation period of max. Seventy-two months (HFrEF 11.6 ± 2.09 mg/dl, P = 0.614, HFpEF 11.2 ± 2.40 mg/dl, P = 0.105).

Focusing on heart failure entity, 12 months prior to pUF, no differences in number of hospitalizations (P = 0.809) and days in hospital (P = 0.746) were detected among HFrEF and HFpEF. After initiation of pUF, total number (2.88 ± 1.62 to 1.25 ± 1.45, P = 0.001) and days of hospitalizations (40.4 ± 31.7 to 18.3 ± 22.5, P = 0.005) significantly decreased in HFpEF, but not in HFrEF patients (2.79 ± 1.70 to 2.09 ± 1.85, P = 0.062; 38.5 ± 27.5 to 29.8 ± 25.9, P = 0.092, respectively) (Fig. 2 a and b).

---

### Brodalumab (Siliq) [^111F5ACX]. FDA (2024). Medium credibility.

Regarding the use of brodalumab SC (also known as Siliq) in patients with peritoneal dialysis:

- Use with caution.

---

### Renal association clinical practice guideline on peritoneal dialysis in adults and children [^114C7FkP]. BMC Nephrology (2017). Low credibility.

These guidelines cover all aspects of the care of patients who are treated with peritoneal dialysis. This includes equipment and resources, preparation for peritoneal dialysis, and adequacy of dialysis (both in terms of removing waste products and fluid), preventing and treating infections. There is also a section on diagnosis and treatment of encapsulating peritoneal sclerosis, a rare but serious complication of peritoneal dialysis where fibrotic (scar) tissue forms around the intestine. The guidelines include recommendations for infants and children, for whom peritoneal dialysis is recommended over haemodialysis. Immediately after the introduction there is a statement of all the recommendations. These recommendations are written in a language that we think should be understandable by many patients, relatives, carers and other interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or 2 depending on the strength of the recommendation by the authors, and A-D depending on the quality of the evidence that the recommendation is based on.

---

### Pertuzumab (Perjeta) [^112XQzqt]. FDA (2025). Medium credibility.

Regarding the use of pertuzumab IV (also known as Perjeta) in patients with peritoneal dialysis:

- Use with caution.

---

### Barium sulfate (vizumax HD) [^114DdqGd]. FDA (2021). Medium credibility.

Los pacientes aprensivos pueden desarrollar debilidad, palidez, tinnitus, diaforesis y bradicardia después de la administración de cualquier agente de diagnóstico. Tales reacciones son generalmente de naturaleza no alérgica.

REACCIONES ADVERSAS: Las reacciones adversas que acompañan el uso de formulaciones de sulfato de bario son infrecuentes y generalmente leves, aunque se han producido reacciones graves (aproximadamente 1 en 500,000) y muertes (aproximadamente 1 en 2,000,000). Las complicaciones del procedimiento son raras, pero pueden incluir neumonitis por aspiración, impactación con sulfato de bario, formación de granuloma, intravasación, embolización y peritonitis después de perforación intestinal, episodios vasovagales y sincopales y muertes. Se ha demostrado que los cambios de EKG ocurren después o durante los enemas de suspensión de sulfato de bario. Es de la mayor importancia estar completamente preparado para tratar cualquier evento de este tipo.

---

### SAGES peritoneal dialysis access guideline update 2023 [^111h5V1T]. Surgical Endoscopy (2024). High credibility.

SAGES peritoneal dialysis access guideline — decision criteria relied on the evidence above and expert opinion; studies actually used similar techniques for AL insertion and image-guided percutaneous insertion, affirming these conclusions, and other criteria may come into play in clinical situations.

---

### Cefuroxime sodium [^1111uKYV]. FDA (2025). Medium credibility.

Regarding the use of cefuroxime sodium IV in patients with peritoneal dialysis:

- Reduce dose.
- Dose as in eGFR < 10 mL/min/1.73 m². Start at a dose of 750 mg. Maximal dose of 1.5 gm. Maximal frequency of q24h.

---

### Diclofenac sodium [^114XiZu2]. FDA (2025). Medium credibility.

Regarding the use of diclofenac sodium DR PO in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.
- Avoid use in patients with residual kidney function.

---

### The removal of uremic solutes by peritoneal dialysis [^114vwdQ8]. Journal of the American Society of Nephrology (2023). Medium credibility.

Abstract

Peritoneal dialysis (PD) is now commonly prescribed to achieve target clearances for urea or creatinine. The International Society for Peritoneal Dialysis has proposed however that such targets should no longer be imposed. The Society's new guidelines suggest rather that the PD prescription should be adjusted to achieve well-being in individual patients. The relaxation of treatment targets could allow increased use of PD. Measurement of solute levels in patients receiving dialysis individualized to relieve uremic symptoms could also help us identify the solutes responsible for those symptoms and then devise new means to limit their accumulation. This possibility has prompted us to review the extent to which different uremic solutes are removed by PD.

---

### Renal association clinical practice guideline on peritoneal dialysis in adults and children [^114QQ2jD]. BMC Nephrology (2017). Low credibility.

Rationale

There is growing evidence that regular use of hypertonic glucose dialysis fluid (3.86%), and where possible glucose 2.27%, is to be avoided as far as possible. It is associated with acceleration in the detrimental changes in membrane function that occur with time on treatment, as well as several undesirable systemic effects including weight gain, poor diabetic control, delayed gastric emptying, hyperinsulinaemia and adverse haemodynamic effects. In addition to patient education to avoid excessive salt and fluid intake, where possible the use of hypertonic glucose should be minimised by enhancing residual diureses with the use of diuretics (e.g. frusemide 250 mg daily). Substituting icodextrin for glucose solutions during the long exchange will result in equivalent ultrafiltration whilst avoiding the systemic effects of the glucose load. Observational evidence would suggest that icodextrin is associated with less functional deterioration in the membrane in APD patients.

Guideline 4.4 – PD: Ultrafiltration and fluid management

We recommend that treatment strategies that favour preservation of renal function or volume should be adopted where possible. These include the use of ACEi, ARBs (in adults only) and diuretics, and the avoidance of episodes of dehydration (1B).

---

### Peritoneal dialysis in patients with congestive heart failure [^114LAwTC]. Nephrology, Dialysis, Transplantation (2006). Low credibility.

Background

Peritoneal dialysis (PD) may be a useful technique in the treatment of patients with congestive heart failure, both with and without primary end-stage renal disease (ESRD).

Methods

In the treatment of patients with ESRD and congestive heart failure (CHF), PD has theoretical advantages compared with haemodialysis (HD), such as the absence of an arteriovenous fistula and the more gradual fluid removal. In cohort studies, the incidence of heart failure was less as compared with HD, however, randomized studies on this aspect are lacking.

Results

As an acute rescue treatment of patients with treatment refractory heart failure, functional improvement has been observed with the use of PD. However, fluid removal is less predictable compared with continuous haemofiltration therapies.

Conclusions

As a long-term option for patients with treatment refractory CHF without ESRD, various case series showed improved functional performance and a reduction in hospitalization with the use of PD. However, also with the use of PD, median survival is still limited in these patients. Randomized studies are needed to establish the potential role of PD for this indication.

---

### Tamsulosin hydrochloride (Flomax) [^111jgWhK]. FDA (2025). Medium credibility.

Regarding the use of tamsulosin hydrochloride PO (also known as Flomax) in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.

---

### Peritoneal dialysis adequacy and risk of death [^111N7MsS]. Current Opinion in Nephrology and Hypertension (2001). Low credibility.

The debate on the relationship between small solute clearance and patient outcome on peritoneal dialysis has intensified in the past year with the publication or presentation of a number of important new studies. Previous studies had found a correlation between clearances and subsequent patient survival. However, this effect was all accounted for by residual renal clearance. The failure to detect an independent effect of peritoneal clearance on outcomes had been attributed to a lack of well-done studies with sufficient variation in peritoneal clearance to detect such an effect. New prospective and randomized studies suggest, however, that the relationship between peritoneal clearance and outcome is weak or absent within the usual dose ranges delivered in clinical practice. Existing clearance targets may need to be reviewed.

---

### IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients [^1137VMDp]. BMC Nephrology (2019). Medium credibility.

Discusion

Transition of non-dialysis-dependent CKD stage 5 to RRT is a crucial moment, both for the patient and the nephrologist. There must be chosen, among other things: when and how to start the RRT, and the delivered dialysis dose. Even though there is not any controlled study that supports this, there has been a tendency towards an early initiation of RRT. Thus, currently in the USA over 50% of patients start with a KrU > 3 mL/min/1.73 m², without reducing morbidity and mortality.

The aim of starting a progressive dialysis treatment, defined as gradual increase of the dose as the RRF volume decline, is to maintain a continuous total clearance of solutes (Kr and Kd). This was proposed in the first guidelines for peritoneal dialysis adequacy, and at present it is highly implemented. Thus, in some countries 30% of patients start with 1 or 2 exchanges/day, or with ≤ 4 sessions/week of automated PD. This is happening in spite of the limited incremental PD studies, in which there is a low number of patients, who are monocentric and not randomized.

Progressive or incremental HD has also become increasingly important over the last years. Performed without economic purposes, it has shown promising results in the RRF maintenance, and the survival is similar to that in conventional HD. In fact, the 3.2 guideline in the KDOQI allows reducing the weekly dose in patients with a KrU higher than 3 ml/min/1.73 m². In these cases, the set objective is to achieve a continuous weekly clearance of 2.3 volumes, expressed in stdKt/v, EKRU of 12-KrU mL/min, both normalized to a volume of 35 L. Such suggestions are based on the strong existing correlation between the RRF and survival; and on their contribution to control the volume and clear protein-bound solutes through tubular secretion. It should be recalled that these are poorly cleared by current techniques, even when the frequency is increased.

---

### Diuretics, limited ultrafiltration, and residual renal function in incident hemodialysis patients: a case series [^1164oTPh]. Seminars in Dialysis (2016). Low credibility.

The effect of diuretics on residual renal function expressed as residual GFR (rGFR) and urine volume (rUV) using 24-hour urine collections has not been well examined in hemodialysis (HD) patients. We present a small (seven patient) but provocative case series describing a strikingly low rate of decline in rUV and rGFR (average of creatinine and urea clearances, 24-hour urine collections) in patients treated with increasing doses of furosemide (up to 360 mg/day) during the first 2 years after initiation of HD. Between 6 and 12 months, the mean rUV fell by 1 ml/month, whereas rGFR declined by 0.03 ml/min/1.73 m² /month. The mean rate of decline from 12 to 24 months for rUV (33 ml/month) and rGFR (0.02 ml/min/1.73 m² /month) were also low. While data are clearly limited and the observation retrospective, they are consistent with the better documented benefit of diuretics observed in end-stage renal disease patients treated with peritoneal dialysis.

---

### Clinical practice guidelines for hemodialysis adequacy, update 2006 [^113Wess8]. American Journal of Kidney Diseases (2006). Medium credibility.

Dialysis modality choice and residual kidney function (RKF) — the Work Group encourages PD (peritoneal dialysis) as a first choice of modality for patients initiating KRT as a means of preserving RKF; however, most patients are not candidates for self-dialysis outside of a clinic, thus HD (hemodialysis) remains the most common initial modality choice for new patients, and the same attention that is given to RKF in PD patients should be directed to the much larger group of HD patients.

---

### Furosemide [^116nDWYb]. FDA (2025). Medium credibility.

Regarding the use of furosemide IV (also known as Lasix, Furoscix) in patients with intermittent hemodialysis:

- Use acceptable.
- No dose adjustment required.

---

### Is hemodiafiltration ready for broader use? [^11658NPa]. Kidney International (2015). Low credibility.

Hemodiafiltration is practiced throughout Europe and in a few additional countries but, because of regulatory restrictions, is not currently available in the United States. Hemodiafiltration removes uremic species more broadly than is achieved by diffusion dialysis, perhaps explaining its better outcome profile.

---

### Ziconotide acetate (Prialt) [^1114T32V]. FDA (2025). Medium credibility.

Regarding the use of ziconotide IT (also known as Prialt) in patients with peritoneal dialysis:

- Use with caution.
- Monitor for urinary retention, myositis and acute kidney injury.

---

### Cefuroxime axetil [^113HKLAW]. FDA (2024). Medium credibility.

Regarding the use of cefuroxime axetil PO (also known as Ceftin, Zinacef) in patients with peritoneal dialysis:

- Dose as in eGFR < 10 mL/min/1.73 m².

---

### Benzocaine (gelato topical anesthetic) [^115rvzyR]. FDA (2022). Medium credibility.

Advertencias

Advertencia de metahemoglobinemia: el uso de este producto puede causar metahemoglobinemia, una afección grave que debe tratarse con pron_tud ya que reduce la cantidad de oxígeno transportado en la sangre. Esto puede ocurrir incluso si ha usado este product anteriormente. Detenga su uso y busque atención médica inmediata si observa que usted o un niño bajo su cuidado presenta:

- piel pálida, gris o azul (cianosis)

- dolor de cabeza

- frecuencia cardíaca rápida

- dificultad para respirar

- mareos o aturdimiento

- fatiga o falta de energía

Alerta de alergia:

No use en pacientes con antecedentes de alergias a anestésicos locales como procaína, butacaína, benzocaína u otros anestésicos de "caína".

No utilice:

- durante más de 7 días a menos que lo indique un médico. Si los síntomas de dolor en la boca no mejoran en 7 días; la irritación, el dolor o el enrojecimiento persisten o empeoran; o si se desarrolla hinchazón, sarpullido o fiebre, consulte a su médico de inmediato.

- para la dentición

- en niños menores de 2 años

Cuando utilice este producto

Evite el contacto con los ojos. En caso que esto ocurra, enjuague con abundante agua fresca.

No exceda la dosis recomendada.

Si se ingiere accidentalmente más de lo recomendado para el dolor, obtenga ayuda médica o

comuníquese con un Centro de control de envenenamiento de inmediato.

---

### Renal association clinical practice guideline on peritoneal dialysis in adults and children [^1154Jb8U]. BMC Nephrology (2017). Low credibility.

Peritoneal dialysis (PD) (guidelines PD 3.1–3.3)

Guideline 3.1 – PD: Solute clearance

We recommend that both residual urine and peritoneal dialysis components of small solute clearance should be measured at least six monthly or more frequently if dependant on residual renal function to achieve clearance targets or if clinically or biochemically indicated in adults and in children. Both urea and/or creatinine clearances can be used to monitor dialysis adequacy and should be interpreted within the limits of the methods (1C).

Guideline 3.2.1 – PD: Solute clearance

We recommend that a combined urinary and peritoneal Kt/V urea of 1.7/week or a creatinine clearance of 50 L/week/1.73 m² should be considered as minimal treatment doses for adults (1A). We recommend/suggest that clearance targets for children should be a minimum of those for adults (1C).

Guideline 3.2.2 – PD: Solute clearance

We recommend that the dose of dialysis should be increased in patients experiencing uraemic symptoms, or inadequate growth in children, even if meeting minimum clearance targets (1B).

Guideline 3.3 – PD: Solute clearance

We recommend that a continuous 24 h PD regime is preferred to an intermittent regime for anuric patients (1B).

---

### The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status [^113B4HUZ]. Nephrology, Dialysis, Transplantation (2009). Low credibility.

Residual renal function, serum albumin, C-reactive protein and safety parameters

No significant changes were obtained in any of these measurements. Plasma and urinary sodium and residual function (see Table 4) and osmolality remained stable throughout the study in all patients. Serum albumin was on average 34.8 ± 3.8 g/l at T 0 and 34.7 ± 4.3 g/l at T 2. C-reactive protein was 4.67 ± 0.59 mg/l at T 0 and 6.01 ± 1.25 mg/l at T 2. There were no significant within-group differences observed.

---

### Three diabetic peritoneal dialysis patients receiving intraperitoneal insulin with dosage adjustment based on capillary glucose levels during peritoneal equilibrium tests [^114RWxSy]. American Journal of Kidney Diseases (2004). Low credibility.

Diabetic patients receiving peritoneal dialysis have vast differences in glucose absorption, significantly affecting glycemic control. Measurement of glucose levels between dialysate exchanges does not adequately reflect these changes. By measuring glucose levels during the peak period of glucose absorption, as determined by a peritoneal equilibrium test, such differences can be measured and accounted for when determining doses of intraperitoneal insulin. In this report, 3 cases in which such an approach was applied are described.

---

### Formoterol fumarate (Foradil) [^1176iF2e]. FDA (2012). Low credibility.

Regarding the use of formoterol fumarate INH (also known as Foradil) in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.

---

### Furosemide (Lasix) [^117N6ZQ8]. FDA (2025). Medium credibility.

Regarding the use of furosemide PO (also known as Lasix, Furoscix) in patients with intermittent hemodialysis:

- Use acceptable.
- No dose adjustment required.

---

### SAGES peritoneal dialysis access guideline update 2023 [^112VTKV3]. Surgical Endoscopy (2024). High credibility.

Implementation considerations — the panel believes that it is feasible to successfully implement these recommendations into local practice and that the recommendations will be accepted by stakeholders, with main considerations including costs and availability of the specialized dialysis personnel, interventional radiology capability, and laparoscopic instrumentation; some techniques require specialized knowledge and skills which may require continuing postgraduate education with didactic and hands-on courses; and to achieve the full benefit of these recommendations, standardizing surgical technique is required.

---

### Furosemide [^116upV7c]. FDA (2025). Medium credibility.

Labeled indications for Furosemide (also known as Lasix, Furoscix) include:

- Treatment of edema in adults with congestive heart failure
- Adjunctive treatment for pulmonary edema in adults
- Treatment of edema in adults with liver cirrhosis
- Treatment of edema in adults with kidney disease

---

### Renal association clinical practice guideline on peritoneal dialysis in adults and children [^112oRFxh]. BMC Nephrology (2017). Low credibility.

Rationale

Observational studies have consistently shown that reduced peritoneal ultrafiltration is associated with worse survival rates; whilst this is seen in studies with or without residual urine, this effect is most marked in anuric patients. In the only prospective study to have pre-set an ultrafiltration target (750 ml/day), patients who remained below this had higher mortality after correcting for age, time on dialysis, comorbidity and nutritional status. It is likely this association is multifactorial, but failure to prescribe sufficient glucose or icodextrin and a lower ultrafiltration capacity of the membrane were factors in this study and should be considered. The European guidelines have suggested a 1 l minimal daily ultrafiltration target but there is insufficient evidence to say that such a target must be met at this stage. It is possible that in some patients with low ultrafiltration, this is appropriate to their low fluid intake, and that in these cases decreased survival possibly results from poor nutrition rather than fluid excess, and that increasing ultrafiltration would simply result in dehydration with its adverse effects. Blood pressure, salt (and fluid) intake, nutritional and fluid status, and presence of any features of uraemia should be taken into account. Nevertheless patients with less than 750 mL ultrafiltration once anuric should be very closely monitored and the potential benefits of modality switch considered.

---

### Are diuretics underutilized in dialysis patients? [^116okQZL]. Seminars in Dialysis (2016). Low credibility.

While oral diuretics are commonly used in patients with chronic kidney disease for the management of volume and blood pressure, they are often discontinued upon initiation of dialysis. We suggest that diuretics are considerably underutilized in peritoneal dialysis and haemodialysis patients despite numerous potential benefits and few side effects. Moreover, when diuretics are used, optimal doses are not always prescribed. In peritoneal dialysis, the use of diuretics can improve volume status and minimize the need for higher glucose-containing solutions. In patients on haemodialysis, diuretics can help lessen interdialytic weight gain, resulting in decreased ultrafiltration rates and fewer episodes of intradialytic hypotension. This paper will review the mechanism of action of diuretics in patients with renal insufficiency, quantify the risk of side effects and elaborate on the potential advantages of diuretic use in peritoneal dialysis and hemodialysis patients with residual kidney function.

---

### Febuxostat [^117Tfno9]. FDA. Low credibility.

Regarding the use of febuxostat PO (also known as Uloric) in patients with intermittent hemodialysis:

- Dose as in eGFR < 10 mL/min/1.73 m². Start at a dose of 40 mg.

---

### KDOQI US commentary on the 2020 ISPD practice recommendations for prescribing high-quality goal-directed peritoneal dialysis [^113wa6mp]. American Journal of Kidney Diseases (2021). High credibility.

Peritoneal dialysis (PD) toxin removal — small-solute clearance targets and monitoring: Removal of toxins may be estimated using Kt/Vurea and/or creatinine clearance, and there is no high-quality evidence regarding the need or benefit associated with a specific target value; the best evidence to date indicates no evidence for a clinically meaningful benefit to intensifying the PD prescription to achieve total Kt/Vurea higher than 1.7. The KDOQI work group stresses that clinicians should follow up patients closely if the delivered dose is below that studied in randomized trials, namely a weekly Kt/V less than 1.7, and notes that recommendation 3d focuses on small-solute clearance to the exclusion of other potential uremic toxins, including molecules of middle molecular weight and protein-bound toxins. There is also no high-quality evidence that incremental PD in those with residual kidney function either improves or worsens mortality, symptoms, or health-related quality of life, and the KDOQI work group suggests that providers closely monitor for uremic symptoms, fluid overload, and protein-energy wasting.

---

### Alfuzosin hcl (Uroxatral) [^111gkP9r]. FDA (2024). Medium credibility.

Regarding the use of alfuzosin hydrochloride ER PO (also known as Uroxatral) in patients with peritoneal dialysis:

- Use with caution.

---

### Peritoneal dialysis vs furosemide to prevent fluid overload in infants… [^112aEGQa]. JAMA Network (2017). Excellent credibility.

Meaning Use of peritoneal dialysis after cardiac surgery is safe and associated with a lower incidence of fluid overload than is furosemide treatment among infants at high risk for postoperative acute kidney injury. Importance Fluid overload after congenital heart surgery is frequent and a major cause of morbidity and mortality among infants. Many programs have adopted the use of peritoneal dialysis for fluid management; however, its benefits compared with those of traditional diuretic administration are unknown. Objective To determine whether infants randomized to PD vs furosemide for the treatment of oliguria have a higher incidence of negative fluid balance on postoperative day 1, as well as avoidance of 10% fluid overload; shorter duration of mechanical ventilation, intensive care unit stay, and inotrope use; and fewer electrolyte abnormalities.

In this randomized clinical trial, we aimed to determine whether the modality of fluid removal is associated with fluid balance and clinical outcomes. We hypothesized that, compared with infants receiving furosemide, infants randomized to PD would be more likely to have a negative fluid balance on postoperative day 1, would be less likely to develop 10% fluid overload, would have less time to negative fluid balance, and would have superior clinical outcomes, including duration of mechanical ventilation, length of stay, vasoactive infusion use, electrolyte level abnormalities, oxygenation indices, and mortality. Patients randomized to furosemide treatment were prescribed 1 mg/kg intravenously every 6 hours for 2 doses, then per physician direction. Chlorothiazide sodium was added on POD 2 at physician discretion.

A urine output of less than 1 mL/kg per hour during the 16 hours after the first furosemide dose was considered to be a poor response, and these patients were allowed to initiate PD or undergo catheter drainage. If patients developed late fluid overload unresponsive to diuretic therapy, PD use was outside the study protocol. We reported adverse outcomes in all 92 randomized and nonrandomized patients undergoing PDC placement. The 2 events were minor and did not affect outcomes. The starting furosemide dose may be less than some would choose in particular scenarios but was chosen to avoid early postoperative hemodynamic instability. The protocol allowed dose increases after the first 2 doses. Patients randomized to the furosemide arm with inadequate diuresis were also allowed to receive dialysis at clinical discretion.

---

### Barium sulfate (vizumax HD) [^112ozmrC]. FDA (2021). Medium credibility.

CONTRAINDICACIONES: Este producto no debe utilizarse en pacientes con perforación gástrica o intestinal conocida o sospechada, pacientes con afecciones que pueden aumentar el riesgo de perforación; hipersensibilidad a los productos de sulfato de bario; sospecha de fístula traqueoesofágica; lesions obstructadoras del intestino delgado; estenosis pilórica; inflamación o lesiones neoplásicas del recto; o en pacientes que han tenido una biopsia rectal reciente.

Las suspensiones de sulfato de bario no deben usarse en niños con trastornos de la deglución o en recién nacidos con obstrucción duodenal o yeyunal completa o cuando se sospecha obstrucción distal del intestino delgado o del colon. La suspensión de sulfato de bario no se recomienda para bebés prematuros muy pequeños y bebés pequeños que requieren pequeños volúmenes de medios de contraste o para bebés y niños pequeños cuando existe la posibilidad de fugas del tracto gastrointestinal, como enterocolitis necrotizante, neumoperitoneo inexplicable, abdomen sin gas, otros perforación intestinal, perforación esofágica o anastomosis postoperatoria.

---

### Peritoneal dialysis prescription and adequacy in clinical practice: core curriculum 2023 [^1158MeYW]. American Journal of Kidney Diseases (2023). Medium credibility.

As the global prevalence of peritoneal dialysis (PD) continues to grow, practitioners must be equipped with prescribing strategies that focus on the needs and preferences of patients. PD is an effective form of kidney replacement therapy that offers numerous benefits to patients, including more flexibility in schedules compared with in-center hemodialysis (HD). Additional benefits of PD include salt and water removal without significant changes in patient hemodynamics. This continuous yet gentle removal of solutes and fluid is associated with better-preserved residual kidney function. Unfortunately, sometimes these advantages are overlooked at the expense of an emphasis on achieving small solute clearance targets. A more patient-centered approach emphasizes the importance of individualized treatment, particularly when considering incremental PD and other prescriptions that align with lifestyle preferences. In shifting the focus from small solute clearance targets to patient needs and clinical goals, PD remains an attractive, patient-centered form of kidney replacement therapy.

---

### SAGES peritoneal dialysis access guideline update 2023 [^113YFk8M]. Surgical Endoscopy (2024). High credibility.

Peritoneal dialysis (PD) catheter dysfunction management requires urgent attention to avoid a lapse in dialysis, with surgeons often assessing and managing these patients and non‑surgical interventions also available.

---

### Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure [^112DRmtt]. Nephrology, Dialysis, Transplantation (2010). Low credibility.

Background

Heart failure (HF) is a major health problem in developed countries. HF is a progressive, lethal disorder, even with adequate treatment. There exists a vicious circle in the pathophysiology of HF that perpetuates and magnifies the problem. Concomitant fluid accumulation may worsen the congestive HF, it is responsible for numerous hospitalizations and it is an important cause of mortality. In this situation, any means of fluid removal may aid in the management of these patients. The objective of this study was to evaluate the efficacy of peritoneal dialysis (PD) in the treatment of refractory HF in terms of functional status, hospitalization and mortality. We also determined the improvement in health-related quality of life with the use of PD, and examined the economic consequences of its use.

Methods

We conducted a single centre, prospective, non-randomized study involving patients showing symptoms and signs of congestive HF refractory to maximum tolerable drug treatment. All of them were treated with PD. We analysed physical and biochemical determinations, functional status (according to the NYHA classification) and echocardiogram parameters. Also, to determine the efficacy of the technique we compared the perceived state of health (measured by the EQ5D) to PD patients respect to those reported with conservative therapies. Finally, we carried out a cost-utility evaluation measured by the incremental cost-utility ratio between these two options.

Results

Seventeen patients (65% men, 64 ± 9 years) were included in the study, and 12 were still undergoing PD treatment at the end of the follow-up period (15 ± 9 months). All patients improved their NYHA functional status (65% two classes; the rest, one; P < 0.001), with an important improvement in their pulmonary artery systolic pressure (44 ± 12 versus 27 ± 9 mmHg; P = 0.007), but no changes in left ventricular ejection fraction. Hospitalization rates underwent a dramatic reduction (from 62 ± 16 to 11 ± 5 days/patient/year; P = 0.003) before and after PD treatment. PD treatment raised life expectancy of 82% after 12 months of treatment, and 70% and 56% after 18 and 24 months, respectively, much better outcomes than those reported about conservative therapies, which only use diverse diuretic regimens. PD was associated with a higher perception state of health than the conservative therapy (0.6727 versus 0.4305; P < 0.01). Finally, we found that PD is cost-effective compared with the conservative therapy.

Conclusions

We demonstrate that congestive HF programmes should consider offering PD in hope of seeing better functional status, reduced morbidity and mortality, better quality of life as well as reduced health care costs.

---

### Febuxostat [^114sA7m2]. FDA. Low credibility.

Regarding the use of febuxostat PO (also known as Uloric) in patients with continuous renal replacement:

- Dose as in eGFR 10–30 mL/min/1.73 m². Start at a dose of 40mg.

---

### Plerixafor (Mozobil) [^112wFaUH]. FDA (2025). Medium credibility.

Regarding the use of plerixafor SC (also known as Mozobil) in patients with peritoneal dialysis:

- Dose as in eGFR < 10 mL/min/1.73 m². Start at a dose of 0.16 mg/kg. Maximal dose of 27 mg. Maximal frequency of q24h.

---

### SAGES peritoneal dialysis access guideline update 2023 [^113iYK8z]. Surgical Endoscopy (2024). High credibility.

SAGES peritoneal dialysis access guideline — methods and intended use explains that this is an evidence-based guideline based on a systematic review of current literature and expert opinion, provides specific recommendations to assist physicians caring for peritoneal dialysis patients, is primarily intended to help surgeons make perioperative decisions for minimally invasive surgery, also aims to educate, inform policy and advocacy, and define future research needs, applies to all physicians facing management uncertainties, indicates preferred but not necessarily the only acceptable approaches, is flexible for individual circumstances, requires surgeons to tailor care to the individual patient, and can be used by patients as a basis for discussion with their surgeon.

---

### Furosemide injection 80 mg / 10 mL (Furoscix) [^114c7Czp]. FDA (2025). Medium credibility.

Regarding the use of furosemide SC (also known as Lasix, Furoscix) in patients with intermittent hemodialysis:

- Use acceptable.
- No dose adjustment required.

---

### Diclofenac sodium [^113j1iJ6]. FDA. Low credibility.

Regarding the use of diclofenac sodium OPHTH (also known as Zorvolex, Voltaren) in patients with peritoneal dialysis:

- Avoid use as much as possible.

---

### Clinical practice guidelines for vascular access [^116uKT8i]. American Journal of Kidney Diseases (2006). Medium credibility.

Peritoneal dialysis patients with modality failure — In the patient receiving peritoneal dialysis (PD) who is manifesting signs of modality failure, the decision to create a backup fistula should be individualized by periodically reassessing need, and in individuals at high risk for failure evaluation and construction should follow the procedures in CPG 1 for patients with CKD stage 4.

---

### Barium sulfate (vizumax HD) [^116efHP6]. FDA (2021). Medium credibility.

DOSIS Y ADMINISTRACIÓN

DOSIS Y ADMINISTRACIÓN: El volumen de sulfato de bario y el método de administración se determinan mediante una técnica individual, y pueden variar según las diferentes características del paciente y del procedimiento. Añadir 65 mL de agua para crear una suspensión de 135 mL con una densidad del 250% p / v (85% p / p). Vuelva a coloquar tapa de forma segura. Invertir la botella y toque con la mano el fondo para aflojar el polvo. Agitar vigorosamente durante 30 segundos y deje reposar al durants 5 minutos. Agregue agua adicional según sea necesario para lograr la% de mezcla deseada. Vuelva a colocar la tapa y agitar nuevamente durante 30 segundos.

DOSIS Y ADMINISTRACIÓN: El volumen de sulfato de bario y el método de administración se determinan mediante una técnica individual, y pueden variar según las diferentes características del paciente y del procedimiento. Añadir 65 mL de agua para crear una suspensión de 135 mL con una densidad del 250% p / v (85% p / p). Vuelva a coloquar tapa de forma segura. Invertir la botella y toque con la mano el fondo para aflojar el polvo. Agitar vigorosamente durante 30 segundos y deje reposar al durants 5 minutos. Agregue agua adicional según sea necesario para lograr la% de mezcla deseada. Vuelva a colocar la tapa y agitar nuevamente durante 30 segundos.

---

### Long-term effects of spironolactone in peritoneal dialysis patients [^111LiqrA]. Journal of the American Society of Nephrology (2014). Low credibility.

ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to high mortality. Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P = 0.03), 18 (P = 0.004), and 24 (P = 0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P = 0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

---

### Cefadroxil [^117BSv6a]. FDA (2025). Medium credibility.

Regarding the use of cefadroxil PO (also known as Duricef) in patients with peritoneal dialysis:

- Start at a dose of 1,000 mg once, then 500 mg q48h.

---

### How has peritoneal dialysis changed over the last 30 years: experience of the verona dialysis center [^114UD4Qo]. BMC Nephrology (2015). Low credibility.

Conclusions

Therefore, the present study, although limited by the exclusion of other important factors that could influence clinical outcomes (including nutritional status, peritoneal transport characteristics) and absence of a control group (i.e. patients undergoing hemodialysis treatment) clearly underlines that in the last decade there has been a significant increment in the number of patients undergoing PD and a profound change in their demographic and clinical characteristics.

Patients are younger, no smokers, with a residual diuresis, normal hemoglobin level and lower blood pressure. All these changes have definitely improved patients' survival (all-causes and cardiovascular diseases) and caused a fall of the hospitalization rate. Moreover, our pre-dialysis care, modifying most of the above reported risk factors, has been a major actor of the clinical improvement observed in our PD patients' population in the last 10 years.

---

### ¿ Quées el metotrexato y Cómo funciona? [^117E6NYt]. Pediatric Dermatology (2023). Medium credibility.

El metotrexato es utilizado desde la década de 1950 para tratar una serie de afecciones. Al inicio se usó en altas dosis para tratar casos de cáncer infantil. El metotrexato en dosis bajas disminuye la inflamación. La inflamación es la causa de algunos problemas dermatológicos. Por esto el metotrexato es utilizado para tratar problemas de la piel.

---

### SAGES peritoneal dialysis access guideline update 2023 [^112ig5n6]. Surgical Endoscopy (2024). High credibility.

SAGES peritoneal dialysis access — KQ7 management of adult peritoneal dialysis catheter malfunction: The panel suggests either operative or nonoperative salvage for adult patients with peritoneal dialysis catheter malfunction (conditional recommendation, very low certainty evidence).

---

### Normalizing the peritoneal dialysis dose-have we got it right? [^112CE62Q]. Kidney International (2016). Low credibility.

How the dialysis dose is normalized is just one of several assumptions that clinicians need to take into account when prescribing peritoneal dialysis. El-Kateb et al. confirm that estimating the volume of urea distribution is associated with significant error and show that energy expenditure is not linearly related to volume, such that there is a potential need for a higher dialysis prescription in smaller, more active individuals.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^112AEqsr]. Developmental Medicine and Child Neurology (2025). Medium credibility.

CRITICA DE LA EVIDENCIA DISPONIBLE

Una limitación importante en muchos de los estudios disponibles es el pequeño tamaño de muestra, con sólo un poco más de un tercio de los estudios incluyendo más de 10 pacientes (mediana = 8.5, rango 1–45). Típicamente, se realizan estudios pequeños cada vez que se prueba el enfoque CO‐OP en una nueva población, en un esfuerzo por proporcionar una prueba de concepto. El principal grupo de niños en los que CO‐OP ha sido validado y se ha establecido como prueba de concepto (y más allá para algunos grupos) incluye TDC, autismo, parálisis cerebral (PC), lesión cerebral adquirida, función ejecutiva y trastornos hipercinéticos de inicio en la infancia, incluyendo trastornos raros de distonía genética.

La literatura muestra que el enfoque de investigación es predominantemente el uso de estudios de caso único con replicas. Aunque se ha informado del uso de estudios de caso único con múltiples líneas base en 10 estudios de CO‐OP, no todos proporcionaron suficientes replicas (mínimo de N‐de‐1 con tres replicas), según guías establecidas. Esto ha permitido el desarrollo de este enfoque con diversas poblaciones, incluyendo trastornos raros.

Sin embargo, se debe prestar más atención a enfoques más robustos para establecer la eficacia mediante un ensayo definitivo (Recomendación 1).

---

### Aldesleukin (Proleukin) [^116Z3n9j]. FDA (2024). Medium credibility.

Regarding the use of aldesleukin IV (also known as Proleukin, Proleukin) in patients with peritoneal dialysis:

- Use with caution.
- Monitor serum creatinine. Monitor blood urea nitrogen.

---

### Febuxostat [^112cqi1j]. FDA. Low credibility.

Regarding the use of febuxostat PO (also known as Uloric) in patients with peritoneal dialysis:

- Dose as in eGFR < 10 mL/min/1.73 m². Start at a dose of 40 mg.

---

### Deferoxamine mesylate (deferoxamine) [^111ZNj9j]. FDA (2025). Medium credibility.

Regarding the use of deferoxamine IV (also known as Desferal) in patients with peritoneal dialysis:

- Maximal dose of 1 g. Maximal frequency of q1–2 weeks.

---

### SAGES peritoneal dialysis access guideline update 2023 [^1165M2Yb]. Surgical Endoscopy (2024). High credibility.

SAGES peritoneal dialysis access guideline — interpretation of recommendation strength states that recommendations use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and are labeled as strong or conditional; the phrase "the guideline panel recommends" denotes strong recommendations while "the guideline panel suggests" denotes conditional recommendations, strong recommendations can be adopted as policy in most situations, conditional recommendations require shared decision-making between the surgeon and patients, and when evidence is insufficient, expert opinion consensus was sought.

---

### Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis [^1114Hrbo]. Kidney International (2001). Low credibility.

Background

Patients on continuous ambulatory peritoneal dialysis (CAPD) are dependent on residual renal function for solute and water clearances, and this declines with time on dialysis. Loop diuretics have been postulated to slow this decline.

Methods

Sixty-one patients new to dialysis were randomly assigned to either furosemide 250 mg every day or no furosemide at the time of CAPD training and were followed prospectively. Urine volume (UV), urea clearance (C(Urea)), and creatinine clearance on cimetidine (C(Cr)) were measured at randomization at six months and at one year. Patients underwent a standard four-hour peritoneum equilibrium test, and total body water was measured by bioelectrical impedance. Results were expressed on an intention-to-treat basis.

Results

UV, C(Cr), and C(Urea) were similar at randomization (1020 ± 104 vs. 1040 ± 130 mL/24 hours, 4.95 ± 0.51 vs. 4.07 ± 0.40 mL/min/1.73 m², 0.91 ± 0.09 vs. 0.84 ± 0.08, diuretic vs. control). UV in the diuretic-treated group increased, whereas in the control group, it declined (+176 vs. -200 mL/24 hours at 6 months and +48.8 vs. -305 mL/24 hours at 1 year, P < 0.05). C(Cr) and C(Urea) declined at a constant rate and were unaffected by diuretic administration (0.12 ± 0.05 vs. 0.071 ± 0.04 mL/min/1.73 m²/month, 0.020 ± 0.01 vs. 0.019 ± 0.01 per month). Urinary sodium excretion increased in the diuretic group and declined in the control group (+0.72 ± 0.85 vs. -2.56 ± 1.31 mmol/24 hours/month, P = 0.04). Body weight rose in both groups (4.3 vs. 3.0 kg), but the percentage of total body weight rose in the control group and remained constant in the diuretic group (52 ± 2.4 vs. 64 ± 6.6%, P = 0.10).

Conclusions

Long-term furosemide produces a significant increase in UV over 12 months when on CAPD and may result in clinically significant improvement in fluid balance. However, furosemide has no effect on preserving residual renal function.

---

### Furosemide injection 80 mg / 10 mL (Furoscix) [^114twrwX]. FDA (2025). Medium credibility.

Regarding the use of furosemide SC (also known as Lasix, Furoscix) in patients with peritoneal dialysis:

- Use acceptable.
- No dose adjustment required.

---

### Peritoneal dialysis in anuric patients: concerns and cautions [^114px4hv]. Seminars in Dialysis (2002). Low credibility.

Most recent studies have found an equivalent survival for patients on peritoneal dialysis (PD) and hemodialysis (HD); evidence even suggests that PD might be the preferred modality during the first 3–4 years of renal replacement therapy. This is probably related to the continuous and minimally invasive character of PD as compared to HD, resulting in better preservation of residual renal function (RRF) and less cardiovascular strain. On the other hand, blood pressure control, fluid balance, and adequacy targets may be difficult to obtain in long-term PD patients. The question arises whether PD is a feasible option in anuric patients. It is clear that the answer depends on the body size and the peritoneal membrane transport characteristics of the patient, so that PD will be feasible in some anuric patients, whereas in others it will not be. Evaluation of the peritoneal transport characteristics and adaptation of the PD prescription is warranted. A constant evaluation of the fluid balance, nutritional, and cardiovascular status is needed. This article reviews the physiologic insights and clinical evidence necessary for a good PD prescription in anuric patients.

---

### Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study [^115CFCLx]. BMC Nephrology (2021). Medium credibility.

Discussion and conclusions

In the first case report, we describe a significant BP reduction associated with chronic use of low-sodium (Na 130 mmol), an uncompensated glucose-based PD solution in a female CAPD patient suffering from resistant hypertension. More specifically, we found a significant decrease in systolic ABP (− 16 mmHg) after 6 months of PD treatment with Na-130 glucose bags in all daily dwells (three per day), with no substantial change in body weight (BW) or anti-hypertensive therapy, suggesting that BP lowering is the consequence of maintenance treatment by Na 130 mmol PD solution. Considering these findings, we used by this low-sodium CAPD solution on a second hypertensive patient with poor BP control. Similarly, we found substantial BP improvement that allowed us to suspend all anti-hypertensive drugs. UF, body weight and residual diuresis remained unmodified too.

These findings are consistent with the results of a recent trial comparing uncompensated Na-125 with standard PD solutions, in which a significant improvement was found in systolic BP (− 17 mmHg) associated with use of low sodium PD solution in the subgroup of patients with lower GFR (< 6 ml/min/1.73 m²), regardless of ultrafiltration. Unlike that previous study, we observed that BP control was independent of residual kidney function (RKF) at the baseline (6.1 ml/min/1.73 m² in the first patient vs 9.9 ml/min/1.73 m² in the second patient). Furthermore, we noticed a reduction in RKF (from 9.9 to 6.0 ml/min/1.73 m²) in the second patient, although no diuresis contraction was found.

---

### Will peritoneal dialysis be left behind? [^116CwY2f]. Seminars in Dialysis (2005). Low credibility.

Peritoneal dialysis (PD) enjoyed huge growth in the 1980s, followed by a rapid decline in the late 1990s, and a now persistently low utilization rate in many countries, including the United States. Recent clinical data indicate a survival advantage for patients started on PD. Residual renal function is better preserved with PD. Adequacy targets are being revised and will likely allow PD prescriptions to be simplified. The physiology of the peritoneum is better understood and treatment strategies reflect that understanding. New solutions have been developed in response to studies that have assessed the impact of conventional PD dialysate on the structure and function of the peritoneum. A remaining challenge is to ensure that nephrology trainees and nephrologists in practice are fully informed of the advantages of PD for many patients and of the advances in the therapy. If this can be achieved, PD should start to grow again.

---

### Revisiting the peritoneal dialysis dose [^113GDzSr]. Seminars in Dialysis (2006). Low credibility.

The question of the minimum dose for adequate peritoneal dialysis has been settled following the publication of two randomized controlled studies and a number of nonrandomized studies. This review summarizes these studies, concluding that these studies support a weekly total Kt/V of 1.7 as the minimum dose, with careful observation for symptoms or signs of uremia and adjustment of the clearance as indicated.

---

### How has peritoneal dialysis changed over the last 30 years: experience of the verona dialysis center [^111S9Zoc]. BMC Nephrology (2015). Low credibility.

However, at the moment, only few reports have pointed out on the identification of risk factors for long-term clinical complications in PD patients living in Italy or other European countries. It is unquestionable that geographically-related characteristics (e.g. diet, health care system), enhancing risk factors, may influence long term clinical outcomes.

Therefore, although monocentric, our study, performed on a large Italian cohort of PD patients (including 260 patients followed by our Renal/Dialysis Unit from 1983 to 2012), has been undertaken to identify changes across the last 30 years, to select clinical elements possibly predicting patients' survival and to recognize targets of intervention useful to minimize the onset and development of severe dialysis-associated clinical complications.

---

### Meropenem [^112H5jC6]. FDA (2020). Medium credibility.

Regarding the use of meropenem IV in patients with peritoneal dialysis:

- Dose as in eGFR < 10 mL/min/1.73 m². Start at a dose of 500mg. Maximal dose of 1g. Maximal frequency of q12h.

---

### The peritoneal-renal syndrome [^116LbgTS]. Nature Reviews: Nephrology (2013). Medium credibility.

In patients on peritoneal dialysis (PD), a strong inter-relationship exists between the peritoneal membrane and the kidney. This Perspectives article will focus on the mechanisms by which alterations in peritoneal membrane function may influence residual renal function and vice versa. In addition, it will discuss how exposure to PD solutions and inhibitors of the renin-angiotensin-aldosterone system can simultaneously affect both the peritoneal membrane and the kidney. Similar to the cardiorenal syndrome, where changes in one organ system result in changes in the other, we propose the existence of a 'peritoneal-renal syndrome', with this novel term encompassing the complex interaction between the peritoneal membrane and the kidneys among patients on PD.

---

### Furosemide injection 80 mg / 10 mL (Furoscix) [^11429yge]. FDA (2025). Medium credibility.

10 OVERDOSAGE

The principal signs and symptoms of overdose with FUROSCIX are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action.

The concentration of furosemide in biological fluids associated with toxicity or death is not known.

Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy).

Hemodialysis does not accelerate furosemide elimination.

---

### The role of peritoneal dialysis in the treatment of refractory heart failure [^113rngv1]. Nephrology, Dialysis, Transplantation (2005). Low credibility.

Heart failure (HF) refractory to conventional therapy is a major and increasing public health and financial problem. Refractory HF is associated with hypervolaemia due to sodium and fluid retention, and azotaemia due to renal hypoperfusion. There is extreme renal salt and water retention and marked secondary hyperaldosteronism. In this state, the kidneys are relatively resistant to diuretic therapy, and the use of very high doses of oral or parenteral diuretics only worsens the renal hypoperfusion, making the patient more azotaemic. A logical treatment for this 'cardiorenal syndrome' is the use of dialysis, which is efficient in treating both the hypervolaemia and azotaemia of refractory HF. Peritoneal dialysis (PD), haemodialysis or continuous veno-venous haemofiltration can and have been used, but the simplest long-term treatment is PD. We present several case reports of the successful use of PD in refractory heart failure. In our opinion, chronic PD is a highly effective mode of treatment for refractory HF, and should be more widely used in this condition.